author-photo

M.P. Chaury

University of Paris

22

Papers

263

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

2013 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (37)
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.

2012 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (10)
Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

2010 Blood
Show All
- Source
- Cite
- Save
Citations (8)
Early Treatment of Anemia of Lower Risk MDS by Erythropoiesis-Stimulating Agents (ESAs): A Report On 112 Cases.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (0)
High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR) +/−G-CSF in Lower-Risk MDS : a Phase II Study.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (21)
L’absence d’expression de IRF4 et de Ki67 définit un sous-groupe de tumeurs de meilleur pronostic parmi les lymphomes indolents à cellules B mémoires

2008
Show All
- Source
- Cite
- Save
Citations (0)
Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM

2008 Blood
Show All
- Source
- Cite
- Save
Citations (2)
C007 Chronic myelomonocytic leukemia (CMML) and CD4+/CD56+ plasmacytoid leukemia are two different phenotypic entities

2007 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (0)
Bortezomib + Low Dose Cytarabine in Int-2 and High Risk MDS. Interim Results of a Phase I/II Trial by the GFM.

2007 Blood
Show All
- Source
- Cite
- Save
Citations (1)